Curve Energy Corp. And Lot 49 Capital Corp. Sign Definitive Agreement for Amalgamation and TSX Venture Listing
VANCOUVER, BC / ACCESS Newswire / March 11, 2025 / Curve Energy Corp. (the "Company" or "Curve") and Lot 49 Capital Corp. ("Lot 49") are pleased to announce that they have entered into a definitive agreement (the "Definitive Agreement") to combine the two companies (the "Transaction") which will constitute a reverse takeover transaction ("RTO") of Lot 49. The Transaction is structured to facilitate the listing of the combined entity on the TSX Venture Exchange ("TSXV").
The Transaction is expected to be completed by way of a three-cornered amalgamation under the provisions of the Business Corporations Act (British Columbia) whereby a wholly-owned subsidiary of Lot 49 ("SubCo"), will amalgamate with Curve. All of the issued and outstanding common shares of SubCo and Curve following the amalgamation will be immediately exchanged for common shares of Lot 49 ("Lot 49 Shares") on a one-for-one basis.
In connection with closing of the Transaction, Lot 49 intends to settle approximately $138,722 of outstanding debt through the issuance of Lot 49 Shares and complete a subscription receipt financing for gross proceeds of approximately $250,000, with such subscription receipts convertible into Lot 49 Shares on closing of the Transaction. After giving effect to the proposed debt settlement and subscription receipt financing, it is anticipated that approximately 2,954,478 Lot 49 Shares will be outstanding immediately prior to closing of the Transaction. In addition, Curve intends to close a non-brokered private placement for gross proceeds of up to $750,000 prior to closing of the Transaction, such that upon completion of the Transaction, it is anticipated that approximately 124,982,673 Lot 49 Shares will be issued to Curve shareholders, giving Curve shareholders ownership of approximately 97.7% of the resulting issuer.
As part of the Transaction, the current board and management team of Lot 49 will be replaced by Curve's existing leadership, ensuring continuity in Curve's strategic vision and operational execution.
"We are excited to take this next step with Lot 49, positioning Curve Energy for growth and innovation in the fuel and refinery technology sector," said Peter Joyce, CEO of Curve. "Our focus remains on advancing proprietary green chemistry solutions that transform the maritime fuel industry while enhancing sustainability across broader fuel markets."
The completion of the Transaction is subject to satisfaction or waiver of customary closing conditions and receipt of certain necessary regulatory approvals, including acceptance by the TSXV. Further details, including timelines and any required shareholder approvals, will be provided as the Transaction progresses.
About Curve Energy Corp.
Curve Energy Corp. is a technology-driven company pioneering advanced green chemistry solutions for the maritime fuel industry and broader energy markets. The company's patented desulfurization technology upgrades Heavy Fuel Oil (HSFO) by removing sulfur, nitrogen, and vanadium, converting it into Very Low Sulfur Fuel Oil (VLSFO) under near-ambient conditions. Curve's technology eliminates the need for carbon-intensive SMR hydrogen desulfurization, blended fuels, and scrubbers, which operate by spraying exhaust gases with seawater, causing a reaction with sulfur oxides that forms sulfuric acid, which is then discharged into the ocean.
Curve's flagship product, Benchmark VLSFO Curve - SR™ (Curve's Straight Run), is engineered to meet both current and anticipated regulatory standards. As global emissions and fuel quality requirements become increasingly stringent, Curve's scalable and environmentally responsible solution offers an industry-leading yield rate, delivering a high-efficiency, low-carbon alternative for maritime and industrial fuel applications. Additionally, Curve's process enhances profitability by enabling the use of discounted feedstocks that alternative solutions cannot efficiently process, unlocking new economic advantages for refiners and fuel suppliers.
The Company's proprietary process produces IMO 2020-compliant VLSFO and operates within a closed-loop system, maximizing yield efficiency while minimizing environmental impact. Curve's Tank-to-Tank System allows seamless scalability and deployment at ports, terminals, and refineries, requiring minimal infrastructure modifications.
Curve is strategically focused on growth and innovation in refining, industrial fuels, and petrochemicals, with near-term objectives including the development of its first commercial-scale plant. Additionally, the Company is advancing digital refinery optimization, leveraging data-driven solutions to enhance operational efficiency and sustainability.
Looking ahead, Curve is positioned to expand into emerging fuel markets, including alternative fuel development, carbon reduction technologies, and advanced refining solutions. As global energy demand evolves, the Company continues to explore new applications, strategic partnerships, and infrastructure deployment opportunities to accelerate sustainable growth and long-term value creation.
For more information about Curve, visit https://www.curvenrg.com
On behalf of the Board of Directors
Peter Joyce
Chief Executive Officer
Forward Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the business plans of Curve and the resulting issuer, the pro forma capital structure of the resulting issuer, the Transaction (including TSXV approval and the closing of the Transaction); completion of the anticipated debt settlement and financings; the efficiency and anticipated applications of the Company's product offerings; and management's beliefs regarding the Company's ability to expand into emerging fuel markets.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things, the risks that: the Company and the resulting issuer will not be able to achieve its business plans; the anticipated pro forma capital structure of the resulting issuer will differ from what is contemplated; the parties may be unable to close the debt settlement and financings; the Company and Lot 49 will be unable to close the Transaction or obtain the requisite third party approvals to close the Transaction; and new laws or regulations could adversely affect the resulting issuer's business and results of operations.
In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the Company and the resulting issuer will be able to carry out its combined business plans as anticipated; the parties will be able to close the debt settlement and financings and will be able to do so on anticipated timelines; and the Company and Lot 49 will receive all necessary third party approvals and will close the Transaction.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
CONTACT:
Peter Joyce
info@curvenrg.com
SOURCE: Curve Energy
View the original press release on ACCESS Newswire
Curve Energy

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release
SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu
Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release
Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom